BioCryst Pharmaceuticals (BCRX) The Citizens JMP Life Sciences Conference 2025 summary

Commercial performance and financial outlook

• Achieved profitability and expects to remain profitable on a full-year basis, with strong cash generation and early debt repayment.

• ORLADEYO, a once-daily oral therapy for hereditary angioedema (HAE), is on track for $580M–$600M in 2024 sales, with a long-term goal of $1B in peak sales.

• Consistent demand growth is driven by efficacy and convenience, with about 60% of patients experiencing excellent results.

• Approximately half of new patients switch from injectable therapies, while the rest are new to therapy or previously used acute treatments.

• U.S. reimbursement rates for ORLADEYO have reached 84%, nearing the 85% target needed for peak sales.

Market dynamics and competitive landscape

• Market research uses comprehensive Monte Carlo simulations to forecast patient, physician, and payer preferences, accurately guiding sales projections.

• Despite new entrants expected by 2030, ORLADEYO and Takhzyro are projected to remain market leaders.

• Patient switching is slow due to satisfaction with current therapies and infrequent physician visits, but the oral formulation offers a compelling reason to switch.

• The pediatric formulation of ORLADEYO is expected to capture most of the estimated 500 U.S. pediatric HAE patients, with strong safety and efficacy data.

• International launches in Europe, Canada, and Japan have shown strong uptake, with reimbursement secured in nearly all major markets.

Pipeline development and future catalysts

• Two clinical programs are advancing: a treatment for Netherton syndrome (phase I, moving to patients this year) and Avoralstat for diabetic macular edema (DME), with patient data expected by year-end.

• Netherton syndrome program targets a population of 3,000–5,000 U.S. patients, aiming for clear disease modification and rapid progression to pivotal trials if data are strong.

• Avoralstat, repurposed for DME, leverages its depot-like properties for targeted retinal delivery, with first patient data expected by year-end.

• The company is prepared to scale commercial and R&D teams as pipeline programs advance, considering partnerships for broader indications.

• Key catalysts in the next 18 months include continued ORLADEYO growth, pediatric NDA progress, and clinical data readouts for Netherton syndrome and DME.